| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1036597858 |
| P356 | DOI | 10.1186/AR579 |
| P932 | PMC publication ID | 3240154 |
| P698 | PubMed publication ID | 12110120 |
| P5875 | ResearchGate publication ID | 11268645 |
| P50 | author | Josef S Smolen | Q66753681 |
| P2860 | cites work | Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome | Q24655734 |
| Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis | Q28239197 | ||
| Defining criteria for autoimmune diseases (Witebsky's postulates revisited) | Q28255257 | ||
| Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor | Q33335777 | ||
| Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity | Q33488126 | ||
| Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. | Q33491307 | ||
| Signal transduction and transcription factors in rheumatic disease | Q33598827 | ||
| Inhibitory pathways triggered by ITIM-containing receptors. | Q33653653 | ||
| p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials | Q33716182 | ||
| Are autoantibodies active players or epiphenomena? | Q48023157 | ||
| Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. | Q52529090 | ||
| Stem cell transplantation for severe autoimmune diseases: progress and problems. | Q54357010 | ||
| Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis | Q57222363 | ||
| Recombinant human Dnase I (rhDNase) in patients with lupus nephritis | Q57232100 | ||
| Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice | Q60998064 | ||
| Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis | Q67815725 | ||
| Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium | Q68395422 | ||
| Effect of treatment on the evolution of renal abnormalities in lupus nephritis | Q71438057 | ||
| Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice | Q71769775 | ||
| Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus | Q71843613 | ||
| Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis | Q73163237 | ||
| Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies | Q73202398 | ||
| Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years | Q73442108 | ||
| The lupus erythematosus cell phenomenon: comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera | Q73490997 | ||
| Fc gamma RIII-mediated production of TNF-alpha induces immune complex alveolitis independently of CXC chemokine generation | Q73720931 | ||
| Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production | Q73994619 | ||
| Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky | Q74242486 | ||
| Severe infections in plasmapheresis-treated systemic lupus erythematosus | Q74324005 | ||
| Effects of anti-B7 monoclonal antibodies on humoral immune responses | Q74520525 | ||
| Rheumatic fever. The relationships between host, microbe, and genetics | Q74600332 | ||
| Virus-associated vasculitides | Q78169183 | ||
| Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. | Q33789658 | ||
| Review article: safety of infliximab in clinical trials | Q33793931 | ||
| Genetic dissection of systemic lupus erythematosus | Q33814991 | ||
| Major peptide autoepitopes for nucleosome-specific T cells of human lupus | Q33853601 | ||
| CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris | Q33855058 | ||
| How to improve morbidity and mortality in systemic lupus erythematosus | Q33902390 | ||
| Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials | Q33925623 | ||
| Current cases in which epitope mimicry is considered as a component cause of autoimmune disease: immune-mediated (type 1) diabetes | Q34114004 | ||
| Control of autoimmunity by regulatory T cells | Q34337530 | ||
| The Th1/Th2 paradigm | Q34429440 | ||
| The Role of the Epstein-Barr virus in human disease | Q34508591 | ||
| Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc | Q35126621 | ||
| Peptide inhibition of glomerular deposition of an anti-DNA antibody | Q36029509 | ||
| Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. | Q36141585 | ||
| Human anti-p68 autoantibodies recognize a common epitope of U1 RNA containing small nuclear ribonucleoprotein and influenza B virus | Q36350643 | ||
| Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome | Q36376711 | ||
| Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis | Q36380818 | ||
| A human autoimmune protein associated with U1 RNA contains a region of homology that is cross-reactive with retroviral p30gag antigen | Q36420467 | ||
| Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice | Q37377479 | ||
| Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. | Q37410508 | ||
| Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2 | Q37652278 | ||
| Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis | Q38294339 | ||
| The natural history of systemic lupus erythematosus by prospective analysis | Q39866953 | ||
| Studies of immune functions of patients with systemic lupus erythematosus. i. dysfunction of suppressor t‐cell activity related to impaired generation of, rather than response to, suppressor cells | Q39873907 | ||
| Intravenous immunoglobulin treatment of lupus nephritis | Q40765749 | ||
| Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains | Q40824882 | ||
| Interleukin-1beta expression is induced by adherence and is enhanced by Fc-receptor binding to immune complex in THP-1 cells | Q41159541 | ||
| Is CTLA-4 a master switch for peripheral T cell tolerance? | Q41350834 | ||
| T cells of lupus and molecular targets for immunotherapy | Q41362966 | ||
| Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms | Q41395974 | ||
| Immune Interferon in the Circulation of Patients with Autoimmune Disease | Q41643954 | ||
| Predisposing factors in sulphasalazine-induced systemic lupus erythematosus | Q42546450 | ||
| A common autoepitope near the carboxyl terminus of the 60-kD Ro ribonucleoprotein: Sequence similarity with a viral protein | Q42617267 | ||
| Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study | Q43692733 | ||
| Interferon-gamma induced exacerbation of systemic lupus erythematosus | Q44566385 | ||
| Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure | Q45737398 | ||
| Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis | Q46376254 | ||
| Treatment of murine lupus with CTLA4Ig | Q46538983 | ||
| Reduction in circulating dsDNA antibody titer after administration of LJP 394. | Q46916879 | ||
| Soluble CD16 in the treatment of murine lupus nephritis | Q47768977 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| P304 | page(s) | S25-30 | |
| P577 | publication date | 2002-05-09 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| Arthritis Research | Q45128333 | ||
| P1476 | title | Therapy of systemic lupus erythematosus: a look into the future | |
| P478 | volume | 4 Suppl 3 |
| Q33961468 | Can estrogens promote hypertension during systemic lupus erythematosus? |
| Q35162962 | Estrogen in cardiovascular disease during systemic lupus erythematosus |
| Q37510905 | Pharmacotherapy of systemic lupus erythematosus. |
| Q36259961 | Prolactin and Dehydroepiandrosterone Levels in Women with Systemic Lupus Erythematosus: The Role of the Extrapituitary Prolactin Promoter Polymorphism at -1149G/T |
| Q37965222 | Systemic lupus erythematosus: a genetic review for advanced practice nurses |
| Q36232715 | Target identification and validation in systemic autoimmunity |
| Q37233020 | The pathophysiology of hypertension in systemic lupus erythematosus |
| Q38777852 | Understanding mechanisms of hypertension in systemic lupus erythematosus |
Search more.